Rapid Readouts: Patient-Reported Outcomes from ADAURA

February 19, 2021
Roy S. Herbst, MD, PhD, Yale Cancer Center

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for patient-reported outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.